Quanterix Corporation

QTRX Healthcare Medical Devices

Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS fell 35.1% and free cash flow grew 18.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

2.87 0.20 −6.51%
Market cap
$145.2M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
3/9
Altman Z
−0.87
Beneish M
−0.69
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 3 1

+8 more TTM periods

ROE
(46.48%) (34.81%) (34.25%) (29.28%)
ROA
(35.41%) (27.30%) (25.97%) (22.37%)
ROIC
(66.50%) (48.03%) (44.21%) (40.08%)
Return on Tangible Assets
(87.51%) (66.28%) (66.48%) (52.65%)
Average Days of Receivables
53.16 67.41 78.76 92.59
Free Cash Flow per Share
(1.73) (1.76) (1.87) (1.48)
Free Cash Flow
(81.68) (82.90) (79.85) (68.22)
Capital Expenditures
(0.76) (1.44) (2.61) (3.12)
Other line items
Cash ROIC
(24.70%) (21.73%) (19.29%) (15.16%)
Accounts Receivable Turnover
6.69 5.27 4.47 4.06
Accounts Payable Turnover
9.44 10.31 7.21 7.76
Inventory Turnover
2.19 1.93 1.69 1.50
Average Days of Payables
38.16 39.85 66.98 58.81
Days of Inventory on Hand
204.29 234.58 270.34 303.98
Tax Rate
(0.02) (0.02) (0.05) (0.05)
Research and Development Expense of Revenue
20.83% 22.91% 25.86% 27.03%
Selling, General and Administrative Expense of Revenue
87.09% 94.23% 99.36% 99.21%
Share Based Compensation of Revenue
12.14% 13.65% 14.92% 16.24%
Operating CF/Net income
0.66 0.78 0.72 0.68
Depreciation/Fixed assets
1.59 1.28 1.00 0.47
Capex/Depreciation
(0.02) (0.05) (0.11) (0.26)
Revenue per Share
3.25 3.09 3.26 2.83
Operating CF per Share
(1.72) (1.73) (1.81) (1.41)
Capex per Share
(0.02) (0.03) (0.06) (0.07)
Capex to Sales
0.01 0.01 0.02 0.02

Fold the line items

Columns are period end dates